Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...

The company’s bacteriophage therapy AP-SA02 achieved an 88% response rate in a Phase 2a trial for Staphylococcus aureus ...

Common infections are becoming more resistant to treatment, and it's leaving experts worried for vulnerable groups.

There are a number of infections, ranging from mild to life-threatening, that can occur when certain bacteria invade the skin ...

Investing.com -- Armata Pharmaceuticals (NYSE American:ARMP) stock surged 95% following the announcement of positive Phase 2a clinical trial results for its bacteriophage treatment targeting ...

Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial.

ATLANTA -- For patients with cardiovascular implantable electronic device (CIED)-associated infections, a shorter course of ...

SINGAPORE – The Republic is reviewing its action plan to better control the emergence and spread of future drug-resistant ...

Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in ...

Armata Pharmaceuticals ($ARMP) stock exploded nearly 300% on Wednesday after the biotech firm released encouraging mid-stage ...

Revium Rx (formerly Revium Recovery Inc. (OTC: RVRC), a biopharmaceutical company developing advanced lipid-based therapeutics for infectious and oncologic diseases, today announced significant ...